research program, mining industry health and safety statistics, and improving miner's health and safety.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Lewis V. Wade, Ph.D., Executive Secretary, MSHRAC, NIOSH, CDC, 200 Independence Avenue, SW., Room 715– H, Hubert Humphrey Building, P12 Washington, DC 20201–0004, telephone 202/401–2192, fax 202/260–4464.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 26, 2003.

#### John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention

[FR Doc. 03–16677 Filed 7–1–03; 8:45 am]
BILLING CODE 4163–19–U

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. 2002N-0354]

Agency Information Collection Activities; Announcement of OMB Approval; The Evaluation of Long-Term Antibiotic Drug Therapy for Persons Involved in Anthrax Remediation Activities

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "The Evaluation of Long-Term Antibiotic Drug Therapy for Persons Involved in Anthrax Remediation Activities" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

# FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of April 2, 2003 (68 FR 16059), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An

agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0494. The approval expires on April 30, 2004. A copy of the supporting statement for this information collection is available on the Internet at <a href="http://www.fda.gov/ohrms/dockets">http://www.fda.gov/ohrms/dockets</a>.

Dated: June 25, 2003.

#### Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. 03–16618 Filed 7–1–03; 8:45 am]
BILLING CODE 4160–01–8

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Food and Drug Administration**

[Docket No. 2002N-0496]

Agency Information Collection Activities; Announcement of OMB Approval; Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition

AGENCY: Food and Drug Administration,

HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Aluminum In Large and Small Volume Parenterals Used in Total Parenteral Nutrition" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

# FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of March 17, 2003 (68 FR 12701), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0439. The approval expires on June 30, 2006. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ ohrms/dockets.

Dated: June 25, 2003.

### Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. 03–16619 Filed 7–1–03; 8:45 am]
BILLING CODE 4160–01–8

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Food and Drug Administration**

[Docket Nos. 97F-0284, 88F-0182, 98F-0706, 98F-0391, 97F-0170, 92F-0315, 99F-4694, 88F-0340, 95F-0021, 99F-0720, 94F-0290, and 00F-1366]

## Withdrawal of Food Additive Petitions Subsequently Converted to Food Contact Notifications

**AGENCY:** Food and Drug Administration, HHS

11115.

**ACTION:** Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing the
withdrawal, without prejudice to a
future filing, of 12 food additive
petitions (FAPs) proposing that the food
additive regulations be amended to
provide for the safe use of certain new
food additives. The petitioners
subsequently requested that their
petitions be converted to food contact
notifications for review under the
agency's new food contact notification
(FCN) program for food contact
substances. The requested uses are now
the subjects of effective notifications.

# **FOR FURTHER INFORMATION CONTACT:** Sylvia Dodson, Center for Food Safety and Applied Nutrition (HFS–275), Food and Drug Administration, 5100 Paint

and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 202–418–3087.

**SUPPLEMENTARY INFORMATION:** In notices published in the Federal Register, on the dates indicated in table 1 of this document, FDA announced the filing of 12 FAPs. These petitions proposed to amend the food additive regulations in the sections listed in the table to provide for the safe use of the listed substances intended for use in food contact articles. Since publication of these filing notices, the petitioners have requested that their respective petitions be converted to FCNs for review under the agency's new FCN process for food contact substances and that their petitions be withdrawn when the corresponding notifications become effective. These petitions were converted to notifications and subsequently reviewed under the FCN process. The requested uses are now the subjects of effective notifications. The corresponding FAPs are now withdrawn